Intercept's NASH therapy heads for submissions after meeting Phase III endpoint

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) intends to submit regulatory applications next half for obeticholic acid (OCA) after new data showed the compound met one of two primary endpoints in the Phase III REGENERATE trial to treat non-alcoholic steatohepatitis. OCA could be the first NASH treatment to reach the market.

At an 18-month analysis, the higher of two doses of

Read the full 571 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE